Intestinal Beh&ccedil;et&rsquo;s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis

doi:10.3748/wjg.v19.i32.5389

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 32

This Article

(342)

(437)

(0)

(5857)

(3)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Case Report

World J Gastroenterol. Aug 28, 2013; 19(32): 5389-5392
Published online Aug 28, 2013. doi: 10.3748/wjg.v19.i32.5389

Full Size Figure Download Figure

Figure 2 In computed tomography, arrow showed bowel wall thickening and prominent enhancement with surrounding fat infiltration at the terminal ileum and cecum. This was suggestive of active inflammation.

Citation: Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. World J Gastroenterol 2013; 19(32): 5389-5392
URL: https://www.wjgnet.com/1007-9327/full/v19/i32/5389.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i32.5389

Chung SH, Park SJ, Hong SP, Cheon JH, Kim TI, Kim WH. Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis. World J Gastroenterol 2013; 19(32): 5389-5392 [PMID: 23983446 DOI: 10.3748/wjg.v19.i32.5389]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.